{
  "hash": "0f07e09485f970708d15cde2e85e522a",
  "result": {
    "markdown": "---\ntitle: Mr Brendan Rearden\nabout:\n  template: solana\n  image-width: 10em\n  image-shape: round\n  links:\n    - icon: twitter\n      text: twitter\n      href: https://twitter.com\n    - icon: github\n      text: Github\n      href: https://github.com\n    - icon: linkedin\n      text: LinkedIn\n      href: https://www.linkedin.com/in/brendan-reardon-ba3b7247/\n    - icon: house-door\n      text: Homepage\n      href: https://www.homepage.com \n    - icon: envelope\n      text: email\n      href: mailto:BrendandotReardon@ul.ie\n\ndescription: \n  Graduate Student\nimage: ../../contents/photos/people/brendanrearden.jpeg\ncard_style: \"summary_large_image\"\ncategories:\n  - PhD Student\n  - eHealth Hub For Cancer\n  - GDI\n---\n\n\n## Mr Brendan Reardon\n\n## Links\n\n[ORCID](https://orcid.org/..)\n\n# Publications\n\nFull list of publications see [Google Scholar](https://scholar.google.com/citations?user=K_J6gxsAAAAJ)\n\nRecent publications include\n\n\n::: {.cell}\n::: {.cell-output .cell-output-stdout}\n```\n[1] S. H. AlDubayan, J. R. Conway, S. Y. Camp, et al. \"Detection of\nPathogenic Variants With Germline Genetic Testing Using Deep Learning\nvs Standard Methods in Patients With Prostate Cancer and Melanoma\".\nEng. In: _JAMA_ 324.19 (Nov. 2020), pp. 1957-1969. ISSN: 1538-3598.\nDOI: 10.1001/jama.2020.20457. PMID: 33201204.\n\n[2] S. H. AlDubayan, L. C. Pyle, M. Gamulin, et al. \"Association of\nInherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With\nSusceptibility to Testicular Germ Cell Tumors\". Eng. In: _JAMA\noncology_ 5.4 (Apr. 2019), pp. 514-522. ISSN: 2374-2445. DOI:\n10.1001/jamaoncol.2018.6477. PMID: 30676620.\n\n[3] M. H. Bailey, C. Tokheim, E. Porta-Pardo, et al. \"Comprehensive\nCharacterization of Cancer Driver Genes and Mutations\". Eng. In: _Cell_\n174.4 (Aug. 2018), pp. 1034-1035. ISSN: 1097-4172. DOI:\n10.1016/j.cell.2018.07.034. PMID: 30096302.\n\n[4] J. Bellmunt, J. Kim, B. Reardon, et al. \"Genomic Predictors of Good\nOutcome, Recurrence, or Progression in High-Grade T1\nNon-Muscle-Invasive Bladder Cancer\". Eng. In: _Cancer research_ 80.20\n(Oct. 2020), pp. 4476-4486. ISSN: 1538-7445. DOI:\n10.1158/0008-5472.CAN-20-0977. PMID: 32868381.\n\n[5] S. Y. Camp, E. Kofman, B. Reardon, et al. \"Evaluating the molecular\ndiagnostic yield of joint genotyping-based approach for detecting rare\ngermline pathogenic and putative loss-of-function variants\". Eng. In:\n_Genetics in medicine : official journal of the American College of\nMedical Genetics_ 23.5 (May. 2021), pp. 918-926. ISSN: 1530-0366. DOI:\n10.1038/s41436-020-01074-w. PMID: 33531667.\n\n[6] J. R. Conway, F. Dietlein, A. Taylor-Weiner, et al. \"Integrated\nmolecular drivers coordinate biological and clinical states in\nmelanoma\". Eng. In: _Nature genetics_ 52.12 (Dec. 2020), pp. 1373-1383.\nISSN: 1546-1718. DOI: 10.1038/s41588-020-00739-1. PMID: 33230298.\n\n[7] J. Crowdis, M. X. He, B. Reardon, et al. \"CoMut: visualizing\nintegrated molecular information with comutation plots\". Eng. In:\n_Bioinformatics (Oxford, England)_ 36.15 (Aug. 2020), pp. 4348-4349.\nISSN: 1367-4811. DOI: 10.1093/bioinformatics/btaa554. PMID: 32502231.\n\n[8] F. Dietlein, D. Weghorn, A. Taylor-Weiner, et al. \"Identification\nof cancer driver genes based on nucleotide context\". Eng. In: _Nature\ngenetics_ 52.2 (Feb. 2020), pp. 208-218. ISSN: 1546-1718. DOI:\n10.1038/s41588-019-0572-y. PMID: 32015527.\n\n[9] C. Gurjao, R. Zhong, K. Haruki, et al. \"Discovery and Features of\nan Alkylating Signature in Colorectal Cancer\". Eng. In: _Cancer\ndiscovery_ 11.10 (Oct. 2021), pp. 2446-2455. ISSN: 2159-8290. DOI:\n10.1158/2159-8290.CD-20-1656. PMID: 34140290.\n\n[10] S. Han, S. Y. Camp, H. Chu, et al. \"Integrative Analysis of\nGermline Rare Variants in Clear and Non-Clear Cell Renal Cell\nCarcinoma\". Eng. In: _medRxiv : the preprint server for health\nsciences_ (Jan. 2023). DOI: 10.1101/2023.01.18.23284664. PMID:\n36712083.\n\n[11] S. C. Kamran, J. K. Lennerz, C. A. Margolis, et al. \"Integrative\nMolecular Characterization of Resistance to Neoadjuvant Chemoradiation\nin Rectal Cancer\". Eng. In: _Clinical cancer research : an official\njournal of the American Association for Cancer Research_ 25.18 (Sep.\n2019), pp. 5561-5571. ISSN: 1557-3265. DOI:\n10.1158/1078-0432.CCR-19-0908. PMID: 31253631.\n\n[12] T. E. Keenan, J. L. Guerriero, R. Barroso-Sousa, et al. \"Molecular\ncorrelates of response to eribulin and pembrolizumab in hormone\nreceptor-positive metastatic breast cancer\". Eng. In: _Nature\ncommunications_ 12.1 (Sep. 2021), p. 5563. ISSN: 2041-1723. DOI:\n10.1038/s41467-021-25769-z. PMID: 34548479.\n\n[13] N. R. Mahadevan, E. H. Knelson, J. O. Wolff, et al. \"Intrinsic\nImmunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular\nPlasticity\". Eng. In: _Cancer discovery_ 11.8 (Aug. 2021), pp.\n1952-1969. ISSN: 2159-8290. DOI: 10.1158/2159-8290.CD-20-0913. PMID:\n33707236.\n\n[14] V. McPherson, B. Reardon, A. Bhayankara, et al. \"A phase 2 trial\nof buparlisib in patients with platinum-resistant metastatic urothelial\ncarcinoma\". Eng. In: _Cancer_ 126.20 (Oct. 2020), pp. 4532-4544. ISSN:\n1097-0142. DOI: 10.1002/cncr.33071. PMID: 32767682.\n\n[15] M. Mossanen, F. L. F. Carvalho, V. Muralidhar, et al. \"Genomic\nFeatures of Muscle-invasive Bladder Cancer Arising After Prostate\nRadiotherapy\". Eng. In: _European urology_ 81.5 (May. 2022), pp.\n466-473. ISSN: 1873-7560. DOI: 10.1016/j.eururo.2021.12.004. PMID:\n34953602.\n\n[16] T. H. Mouhieddine, A. S. Sperling, R. Redd, et al. \"Clonal\nhematopoiesis is associated with adverse outcomes in multiple myeloma\npatients undergoing transplant\". Eng. In: _Nature communications_ 11.1\n(Jun. 2020), p. 2996. ISSN: 2041-1723. DOI: 10.1038/s41467-020-16805-5.\nPMID: 32533060.\n\n[17] B. Reardon, N. D. Moore, N. S. Moore, et al. \"Integrating\nmolecular profiles into clinical frameworks through the Molecular\nOncology Almanac to prospectively guide precision oncology\". Eng. In:\n_Nature cancer_ 2.10 (Oct. 2021), pp. 1102-1112. ISSN: 2662-1347. DOI:\n10.1038/s43018-021-00243-3. PMID: 35121878.\n\n[18] J. M. Rusert, E. F. Juarez, S. Brabetz, et al. \"Functional\nPrecision Medicine Identifies New Therapeutic Candidates for\nMedulloblastoma\". Eng. In: _Cancer research_ 80.23 (Dec. 2020), pp.\n5393-5407. ISSN: 1538-7445. DOI: 10.1158/0008-5472.CAN-20-1655. PMID:\n33046443.\n\n[19] J. Schiantarelli, T. Pappa, J. Conway, et al. \"Mutational\nFootprint of Platinum Chemotherapy in a Secondary Thyroid Cancer\". Eng.\nIn: _JCO precision oncology_ 6 (Aug. 2022), p. e2200183. ISSN:\n2473-4284. DOI: 10.1200/PO.22.00183. PMID: 36075011.\n\n[20] D. Van Egeren, K. Kohli, J. L. Warner, et al. \"Genomic analysis of\nearly-stage lung cancer reveals a role for TP53 mutations in distant\nmetastasis\". Eng. In: _Scientific reports_ 12.1 (Nov. 2022), p. 19055.\nISSN: 2045-2322. DOI: 10.1038/s41598-022-21448-1. PMID: 36351964.\n```\n:::\n:::\n",
    "supporting": [],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {},
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}